Inclusion Criteria:

- HIV-1 infection

- T CD4 cell count number above 200 /mm3

- History of 2 to 4 injections of Hepatitis B vaccine, at any time in the past

- No history of Hepatitis B vaccination with a double-dose schedule

- No response to Hepatitis B vaccination: serology Hepatitis B negative (AgHBs, AbHBs
and AbHBc negative) the previous twelve months and at the screening visit

- AbHBs titers below 10 IU/ml four weeks after the boost of Genhevac-B® 20μg preceding
the randomization

- unchanged ARV treatment for the last 2 months for patients who are receiving ARV at
the screening visit

- Undetectable HIV RNA for the last 6 months and on-going ARV for any patients with T
CD4 cell level below 350/mm3

- HIV-1 plasma load below 100 000 copies per ml for patients without ARV

- Negative pregnancy test at the screening visit, and immediately before the
Genhevac-B® 20 µg boost injection preceding the randomization

Exclusion Criteria:

- Acute cytolysis in the last 3 months with transaminases equal or above 5 times the
upper limit of normal for HIV-HCV coinfected patients, or transaminases equal or
above 2 times the upper limit of normal for non coinfected patients

- Any vaccine received during the month preceding the inclusion

- History of hypersensitivity to any component of GenHevac-B

- acute opportunistic infection treated the month before the screening visit

- Severe and acute pyretic infection or unexplained fever the week before inclusion

- Hemopathy or solid-organ cancer

- Prothrombin factor equal or below 50% and/or platelets equal or below 50 000 per mm3

- Immunosuppressive treatment or general corticotherapy (equal or above 0,5 mg per kg
per day during at least 7 days) in the last 6 months before the screening visit

- Immunomodulating treatment (interferon, interleukine-2,…) in the last 6 months before
the screening visit

- Splenectomy

- Decompensated cirrhosis (Child Pugh B or C)

- Renal failure (creatinine clearance below 50 ml/mn)

- Other severe immunocompromised condition not related to HIV infection (solid-organ
transplantation, chemotherapy in the last 6 months,….)

- Any participation to another clinical trial plan until Week 28